Neotigason (acitretin)

Information for healthcare professionals

Pregnancy Prevention Programme

Oral retinoids, including Neotigason (acitretin) are highly teratogenic and must not be used during pregnancy.

Neotigason is therefore strictly contraindicated during pregnancy and in women of childbearing potential, unless all conditions of the Neotigason Pregnancy Prevention Programme are ful­filled.

Educational materials for Neotigason (acitretin) for healthcare professionals are available below:

Prescriber checklist


Pharmacist checklist


Educational materials for Neotigason (acitretin) for patients are available below:

Patient reminder card


Further information (such as how to take Neotigason, special warnings and possible side effects) is included in the Summary of Product Characteristics (SmPC).

The SmPC for Neotigason 10 mg capsules and Neotigason 25 mg capsules are available to download on the Health Products Regulatory Authority (HPRA) website here.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at

You can also report side effects to Teva via our online form.

If you have any queries please contact Teva’s Medical Information team on +44 207 540 7117 or email

Date of preparation: January 2023
Reference: COB-IE-NP-00043